<DOC>
	<DOCNO>NCT00992407</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety long act injectable ( LAI ) risperidone oral risperidone treatment participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) schizoaffective disorder ( mixed psychiatric disorder relate complex psychotic state feature schizophrenia mood disorder bipolar disorder ) .</brief_summary>
	<brief_title>An Efficacy Safety Study Long Acting Injectable Risperidone Oral Risperidone Participants With Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description>This randomize ( treatment group assign chance ) , open-label ( involved people know identity study drug ) , active-controlled study evaluate improvement social functioning among participant schizophrenia take LAI risperidone oral risperidone tablet . The study drug administer 52 week flexible dose ( range per Investigator 's discretion ) total 11 assessment visit conduct per participant , include Screening . The participant may withdraw trial medical reason sole discretion investigator . Before start study treatment , participant undergo period switch previous medication risperidone 4 week , evaluate tolerability 2 week ( run-in period stabilize risperidone ) . In 2-week period , participant take oral risperidone . The efficacy primarily evaluate Personal Social Performance Scale . Safety evaluate Abnormal Involuntary Movement Scale , Barnes Akathisia Rating Scale , Simpson-Angus Rating Scale . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Participants understand objective necessary procedure study sign informed consent form specify willing participate study Participants schizophrenia schizoaffective disorder require longterm antipsychotic drug therapy Participants premorbid global assessment function score 71 high Screening Participants present clinically significant abnormality biochemistry electrocardiography Participants compliant study requirement ( , fill questionnaire ) capable actually perform willing implementing Participants take clozapine past three month Participants mental retardation ( Intelligence Quotient le 70 screening ) Participants history currently serious disease ( cardiovascular , respiratory , neurological [ include seizure significant cerebrovascular ] , renal , hepatic , hematologic , endocrine , immunologic systemic disease ) include clinically relevant abnormal level Participants allergic hypersensitive reaction risperidone unresponsive risperidone Pregnant lactate female participant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Risperdal</keyword>
</DOC>